Australian investigators presented the WhiMSICAL database at the American Society of Haematology (ASH) 59th annual meeting with 25,000 attendees discussing the latest advances in blood disease treatment.
ASH presentation author Dr Ibrahim Tohidi-Esfahani and co-Principal Investigator a/Prof Judith Trotman with the WhiMSICAL database poster at the American Society of Haematology 59th annual meeting on 9 December 2017
Australian Principal Investigators presented on WhiMSICAL database at the American Society of Haematology (ASH) 59th annual meeting. 25,000 haematologists at ASH discussed the latest advances in blood disease treatment.
The poster is available at 171205 WhiMSICAL ASH 2017 Poster
The key points of the WhiMSICAL database abstract and poster presentation include:
- WhiMSICAL demonstrated as a robust data collection platform with feasibility of global use for WM patient-derived data
- WhiMSICAL results appear comparable to registry data and formal validation is planned
- WhiMSICAL will increase knowledge of presentations and treatment experiences of WM patients with an expanding body of “big data” from recruitment and ongoing data entry
- WhiMSICAL has the potential to map real-world therapy compliance and efficacy along with global patterns of treatment access
The presentation at ASH was backed internationally by IWMF and Lymphoma Coalition. The authorship of the ASH abstract including leading haematologists from the US, UK, The Netherlands, France and NZ should assist WhiMSICAL gain traction in the world medical community. We are a quarter of the way to achieving the required 1,000 in the database for “big data”. Strong WM patient support with medical community encouragement are the keys for future success.
Highlights from the WhiMSICAL database poster include:
- The 279 participants were predominantly from the USA (45%) and Australia (23%)
- Median age at participation was 67 years and at diagnosis 60 years
- Fatigue was the most common symptom at diagnosis (44%)
- From diagnosis to first treatment median time was 82 days
- Forty different first-line therapeutic combinations were entered by 173 patients
- Most patients had only one line of therapy (47%) or were untreated (24%)
Details about WhiMSICAL database are at http://www.wmozzies.com.au/index.php/whimsical/